Q-omics provides the consensus-scored RNF150 profile across patient tissues and cancer cell-line models. RNF150 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, RNF150 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, RNF150 RNA expression shows 19,395 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCS, KIRC, and UVM as cancer lineages where RNF150 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNF150 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNF150 survival associations across molecular data types. RNF150 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNF150 RNA expression–survival associations across cancer types. High RNF150 expression shows unfavorable associations in MESO, but favorable associations in UCS, HNSC, LGG, CESC and KIRC. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for RNF150 RNA expression.
This table summarizes RNF150 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RNF150. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNF150 shows lower tumor expression in KIRC, THCA, KIRP, COAD, HNSC and BLCA. The KIRC box plot shows higher RNF150 RNA expression in normal versus tumor tissue (log2 FC = −3.160, t-test p < 0.001).
This table shows molecular features associated with RNF150 in patient tissues and cancer cell lines. In patient samples, RNF150 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, RNF150 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
